12:00 AM
 | 
Aug 17, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AYX1: Phase IIb data

The double-blind, U.S. Phase IIb ADYX-003 trial in 120 patients who underwent knee replacement surgery showed that a single preoperative intrathecal injection of AYX1 plus standard of care (SOC) met the primary endpoint of reducing pain with walking from day 7 to day 28 vs. placebo plus...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >